Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short-term Investments (2016 - 2024)

Myriad Genetics (MYGN) has disclosed Short-term Investments for 15 consecutive years, with $4.9 million as the latest value for Q2 2024.

  • Quarterly Short-term Investments fell 73.94% to $4.9 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Jun 2024, down 73.94% year-over-year, with the annual reading at $8.8 million for FY2023, 84.83% down from the prior year.
  • Short-term Investments for Q2 2024 was $4.9 million at Myriad Genetics, down from $7.4 million in the prior quarter.
  • The five-year high for Short-term Investments was $103.2 million in Q1 2022, with the low at $4.9 million in Q2 2024.
  • Average Short-term Investments over 5 years is $46.4 million, with a median of $44.0 million recorded in 2020.
  • The sharpest move saw Short-term Investments soared 279.41% in 2022, then plummeted 87.52% in 2023.
  • Over 5 years, Short-term Investments stood at $33.7 million in 2020, then surged by 141.54% to $81.4 million in 2021, then dropped by 28.75% to $58.0 million in 2022, then crashed by 84.83% to $8.8 million in 2023, then plummeted by 44.32% to $4.9 million in 2024.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $4.9 million, $7.4 million, and $8.8 million for Q2 2024, Q1 2024, and Q4 2023 respectively.